- Home
- HOLO vs BDRX Comparison
HOLO vs BDRX Comparison
Compare HOLO & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOLO | BDRX |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.2M | 4.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HOLO | BDRX |
|---|---|---|
| Price | $2.63 | $2.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 533.3K | ★ 2.8M |
| Earning Date | 08-10-2023 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 13.81 | N/A |
| Revenue | ★ $44,840,587.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.19 | ★ N/A |
| Revenue Growth | ★ 37.10 | N/A |
| 52 Week Low | $2.57 | $2.22 |
| 52 Week High | $370.00 | $92.00 |
Technical Indicators
Market Signals| Indicator | HOLO | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.62 | 38.39 |
| Support Level | $2.57 | $2.22 |
| Resistance Level | $3.26 | $7.22 |
| Average True Range (ATR) | 0.23 | 0.70 |
| MACD | -0.02 | -0.23 |
| Stochastic Oscillator | 6.16 | 3.20 |
Price Performance
Historical ComparisonAbout HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.